Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Income towards Parent Company (2016 - 2025)

Haemonetics (HAE) has 17 years of Income towards Parent Company data on record, last reported at $44.7 million in Q4 2025.

  • For Q4 2025, Income towards Parent Company rose 19.24% year-over-year to $44.7 million; the TTM value through Dec 2025 reached $175.4 million, up 34.87%, while the annual FY2025 figure was $167.7 million, 42.64% up from the prior year.
  • Income towards Parent Company reached $44.7 million in Q4 2025 per HAE's latest filing, up from $38.7 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $58.0 million in Q1 2025 and bottomed at -$11.0 million in Q2 2021.
  • Average Income towards Parent Company over 5 years is $27.5 million, with a median of $32.1 million recorded in 2022.
  • Peak YoY movement for Income towards Parent Company: tumbled 162.61% in 2021, then surged 551.32% in 2022.
  • A 5-year view of Income towards Parent Company shows it stood at $14.9 million in 2021, then soared by 121.76% to $32.9 million in 2022, then dropped by 5.21% to $31.2 million in 2023, then increased by 20.15% to $37.5 million in 2024, then rose by 19.24% to $44.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Income towards Parent Company were $44.7 million in Q4 2025, $38.7 million in Q3 2025, and $34.0 million in Q2 2025.